Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Human Milk Fortification in Extremely Preterm Infants (N-forte)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03797157
Recruitment Status : Not yet recruiting
First Posted : January 9, 2019
Last Update Posted : January 9, 2019
Sponsor:
Collaborators:
Sahlgrenska University Hospital, Sweden
Region Uppsala
Vasterbottens lans landsting
Prolacta Bioscience
Information provided by (Responsible Party):
Thomas Abrahamsson, Ostergotland County Council, Sweden

Brief Summary:

This is a randomised controlled multi-centre trial comparing the effect of diet supplementation of a human breast milk-based nutrient fortifier (H2MF®) with standard bovine protein-based nutrient fortifier in 222 extremely preterm infants (born before gestational week 28+0) exclusively fed with human breast milk (own mother´s milk and/or donor milk). The infants will be randomised to receive either the human breast-milk based H2MF® or the standard bovine protein-based nutrient fortifier when oral feeds have reached <100 ml/kg/day.

The randomised intervention, stratified by centre, will continue until the target gestational week 34+0. The infant must not be fed with formula during the intervention period. The allocation will be concealed before inclusion, but after randomisation the study is not blinded.

Primary endpoint of the intervention is the composite variable necrotizing enterocolitis (NEC), sepsis and mortality.

The enrolled infants are characterised with clinical data including growth, feeding intolerance, use of enteral and parenteral nutrition, treatment, antibiotics and complications collected daily in a study specific case report form from birth until discharge from the hospital (not longer than gestational week 44+0). A follow up focusing on neurological development, growth and feeding problems will be performed at 2 years of age (corrected) and 5.5 years of age.


Condition or disease Intervention/treatment Phase
Necrotizing Enterocolitis Sepsis Morality Dietary Supplement: H2MF Dietary Supplement: Bovine milk-based fortifier Phase 2 Phase 3

Detailed Description:

This is a randomised controlled multi-centre trial comparing the effect of diet supplementation of a human breast milk-based nutrient fortifier (H2MF®) with standard bovine protein-based nutrient fortifier in 222 extremely preterm infants (born before gestational week 28+0) exclusively fed with human breast milk (own mother´s milk and/or donor milk). The infants will be randomised to receive either the human breast-milk based H2MF® or the standard bovine protein-based nutrient fortifier when oral feeds have reached <100 ml/kg/day. If fortification with extra enteral lipids is needed during the intervention period, the infants receiving H2MF® will be supplemented with the human milk-based Prolact CR®, while the infants receiving standard bovine protein-based fortification will be supplemented with the standard lipid products used at the unit. The study subject will be enrolled at level III neonatal intensive care unit (NICU)s. Only infants with a home clinic with the logistics to maintain the intervention until gestational week 34+0 will be included.

The randomised intervention, stratified by centre, will continue until the target gestational week 34+0. The infant must not be fed with formula during the intervention period. The allocation will be concealed before inclusion, but after randomisation the study is not blinded. It would not be possible to prescribe the fortifier and prepare of the breast milk in a blinded fashion, since the fortifiers are not exactly equal in nutrient content and also look different. Instead the assessment of several of the outcomes will be made blinded, such as the assessment of X-ray images in NEC cases.

The enrolled infants are characterised with clinical data including growth, feeding intolerance, use of enteral and parenteral nutrition, treatment, antibiotics and complications collected daily in a study specific case report form from birth until discharge from the hospital (not longer than gestational week 44+0). A follow up focusing on neurological development, growth and feeding problems will be performed at 2 years of age (corrected).

Since it is often difficult to distinguish between the diagnoses of NEC and sepsis, and their clinical consequences, the investigator's primary endpoint of the intervention is the composite variable NEC, sepsis and mortality. Secondary endpoints are feeding intolerance and other severe complication such as Bronchopulmonary dysplasia (BPD), Retinopathy of prematurity (ROP) and neurological impairment. Stool, urine and blood samples are also collected for microbiology, metabolomic and immunology analysis in order to study underlying mechanisms. Health economic analyses will be made to evaluate the costs and benefits of an introduction of human milk-based fortifier in NICUs in the Nordic countries.

Analyses will be conducted using an intention to treat approach. An evaluation will be performed when 20 infants have been included to evaluate feasibility and make it possible to adjust the protocol for the remaining part of the study. Safety analyses will be performed by an independent data and safety monitoring board (DSMB) when 50, 100 and 150 infants have been included. A sample size re-estimation will be made by an independent statistician when 150 infants have been included. Thus, the definitive sample size might be increased (never decreased) based on this interim analysis. The study can be terminated before 322 infants have been enrolled based on a decision of the sponsor and the DSMB, if the primary outcome is significantly lower (with a significance level <0.001) in the H2MF® than in the standard fortification group in the interim analysis made after 150 infants have completed the neonatal period. The study subject will be enrolled at level III NICUs in the Nordic Countries. All study subjects will be followed during the neonatal period until discharge (not longer than gestational week 44+0) and also be included in a follow up at 2 and 5.5 years of age based on the national follow up program for extremely preterm infants.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 222 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Nordic Study on Human Milk Fortification in Extremely Preterm Infants: a Randomized Controlled Trial
Estimated Study Start Date : January 1, 2019
Estimated Primary Completion Date : April 30, 2022
Estimated Study Completion Date : December 31, 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis

Arm Intervention/treatment
Experimental: H2MF
Human milk-based breast milk fortifier
Dietary Supplement: H2MF
H2MF is a human milk-based breastmilk fortifier for preterm infants

Active Comparator: Standard fortifier
Standard care: bovine milk-based breast milk fortifier
Dietary Supplement: Bovine milk-based fortifier
Bovine milk-based fortifier is the standard breast milk fortifier in Sweden




Primary Outcome Measures :
  1. The incidence of the composite of necrotizing enterocolitis, culture-proven sepsis and mortality [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    An infant should have had any of these diagnoses to fulfil the criterion


Secondary Outcome Measures :
  1. Time to reach full enteral feeds [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    The day of life the infant has received at least 150 mL/kg enteral feeds

  2. Number of feeding interruptions [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Number of days feedings held for ≥12 hours or feeds reduced by >50% (ml/kg/d) not due to a clinical procedure or transitioning to the breast

  3. Numbers of days with parenteral nutrition [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Number of days of parental amino acid and/or lipid infusion. Only days when the enteral feed <150mL/kg/day should be included

  4. Number of large gastric aspirates per day [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    ≥100% pre-feed volume (2 hours feeding volume if continuous feeding). Lower limit=2 ml/kg.

  5. Stool frequency [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  6. Time to regain birth weight [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  7. Change in head circumference in centimeters [ Time Frame: At 7, 14, 21 and 28 days, the end of intervention (gestational week 34+0), gestational week 36+0, at discharge from neonatal ward (or at gestational week 44+0, whatever comes first) and at 2 years of age (corrected) and 5.5 years of age (uncorrected). ]
  8. Change in weight in gram [ Time Frame: At 7, 14, 21 and 28 days, the end of intervention (gestational week 34+0), gestational week 36+0, at discharge from neonatal ward (or at gestational week 44+0, whatever comes first) and at 2 years of age (corrected) and 5.5 years of age (uncorrected). ]
  9. Change in length in centimeters [ Time Frame: At 7, 14, 21 and 28 days, the end of intervention (gestational week 34+0), gestational week 36+0, at discharge from neonatal ward (or at gestational week 44+0, whatever comes first) and at 2 years of age (corrected) and 5.5 years of age (uncorrected). ]
  10. The mortality incidence [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  11. The incidence of necrotising enterocolitis: Bell´s stage II-III [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  12. The incidence spontaneous intestinal perforation [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  13. The incidence of abdominal surgery [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  14. The incidence culture-proven sepsis [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  15. The incidence of suspected sepsis, not culture-proven [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
  16. The incidence of pneumonia [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Pathological X-ray confirmed by an independent radiologist, need of increased respiratory support/oxygen and laboratory inflammatory response

  17. The incidence of bronchopulmonary dysplasia [ Time Frame: At gestational week 36+0 ]
    Need of extra oxygen, continuous positive air pressure (CPAP) or ventilator at gestational week 36+0

  18. The incidence of retinopathy of the prematurity [ Time Frame: From birth until gestational week 42+0 ]
    Classified into stage I-V. The diagnosis is set after gestational week 42+0

  19. The incidence of intraventricular haemorrhage [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Classified into grade I-IV according to Papile

  20. The incidence of periventricular leukomalacia [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Criteria according to de Vries

  21. Number of days with intensive care [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Need of respirator or CPAP until discharge (not later than gestational week 44+0).

  22. Length of stay at the hospital [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Gestational week and day at discharge (not later than gestational week 44+0).

  23. Length of need of feeding tube [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    Gestational week and day when the infant does not need it anymore (not later than gestational week 44+0)

  24. Neurocognitive development at 2 years [ Time Frame: At 2 years of age ]
    Bayleys III

  25. Prevalence of cerebral palsy at 2 years [ Time Frame: At 2 years of age ]
  26. Prevalence of epilepsy at 2 years [ Time Frame: At 2 years of age ]
  27. Prevalence of squint and/or impaired vision at 2 years [ Time Frame: At 2 years of age ]
  28. Prevalence of impaired hearing at 2 years [ Time Frame: At 2 years of age ]
  29. The number of infants needing extra oxygen and/or ventilatory support after discharge from the hospital at the neonatal period [ Time Frame: From gestational week 44 until 2 years of age ]
  30. The incidence of wheeze and/or asthma [ Time Frame: From birth until 2 years of life ]
  31. The incidence of severe infections after discharge from the neonatal unit [ Time Frame: From gestational week 44 until 2 years of age ]
  32. The number of infants needing feeding tube after discharge from the hospital at the neonatal period [ Time Frame: From gestational week 44 until 2 years of age ]
  33. The number of infants needing extra nutritional support after discharge from the hospital at the neonatal period [ Time Frame: From gestational week 44 until 2 years of age ]
  34. The prevalence of neurocognitive development at 5.5 years [ Time Frame: At 5.5 years of age ]
    Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV TM) and Movement ABC-2: the total scale points as well as the points of sub scales (motor, cognitive, language) will be presented. The prevalence of infants with a realist below 2 standard deviations will be defined to have mental retardation.

  35. The prevalence of cerebral palsy at 5.5 years [ Time Frame: At 5.5 years of age ]
  36. The prevalence of epilepsy at 5.5 years of age [ Time Frame: At 5.5 years of age ]
  37. The prevalence of squint and/or impaired vision at 5.5 years of age [ Time Frame: At 5.5 years of age ]
  38. The prevalence of children with impaired hearing at 5.5 years of age [ Time Frame: At 5.5 years of age ]
  39. The prevalence of wheeze and/or asthma at 5.5 years of age [ Time Frame: At 5.5 years of age ]
  40. Microbiome composition in stool samples [ Time Frame: At 1, 2, 3 and 4 weeks of age and gestational week 36+0 ]
    The relative abundance and diversity of microbial taxa will be analyses with next generation sequencing and be related till the study intervention

  41. Levels of subclasses of T and B cells and granulocytes in blood samples [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    T helper subsets (TH1, Th2, TH17, Treg), T cells subsets associated with the intestinal mucosa (gamma/delta-T cells, MAIT cells) and neutrophils will be assessed using masscytometry

  42. Levels of immune markers in plasma [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    Pre planned analyses are anti-inflammatory (e.g. IL-10) and proinflammatory (e.g. TNF) cytokines and chemokines (e.g. CXCL11, CCL18).

  43. Levels of growth factors in plasma samples [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    The levels of growth factors such as IGF-1 and the associated IGFBP-3 will be analysed.

  44. Levels of lipids in plasma samples [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    Fatty acids in plasma

  45. Levels of neurotransmitters in plasma samples [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    Neurotransmitters such as GABA and serotonin in plasma

  46. Levels of markers of central nervous system (CNS) damage in plasma samples [ Time Frame: At 1, 2 and 4 weeks of age and gestational week 36+0 ]
    Markers of CNS damage such as neurofilament light protein will be measured in plasma

  47. Levels of metabolic peptides in urine samples [ Time Frame: At 1, 2, 3 and 4 weeks of age and gestational week 36+0 ]
    Metabolic peptide will be measured with proton nuclear magnetic resonance spectroscopy (NMR), liquid chromatography (LC) and mass spectroscopy couple to gas chromatography (GC-MC).

  48. Levels of proteins in breast milk samples [ Time Frame: At 1, 2, 3 and 4 weeks of age and gestational week 36+0 ]
    Protein composition will be measured with multiplex methods

  49. Levels of human milk oligosaccharides in breast milk samples [ Time Frame: At 1, 2, 3 and 4 weeks of age and gestational week 36+0 ]
    The levels of human milk oligosaccharides will be measured with high-performance anion-exchange chromatography with pulsed amperometric detection.

  50. Health care costs [ Time Frame: From birth until discharge from hospital (but not loner than gestational week 44+0) ]
    The number of days at each level of care will be recorded until discharge from the hospital (not longer than gestational week 44+0). The cost will be calculated by multiplying the number of days at each level of care by the average cost



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Gestational age at birth 22+0-27+6: based on prenatal ultrasonography.
  • Enteral feeds < 100 mL/kg/day at the day of randomisation.
  • Written informed consent from the legal guardians of the infant.
  • The home clinic of the infant has the logistics of maintaining the intervention until gestational week 34+0

Exclusion Criteria:

  • Lethal or complicated malformation known at the time of inclusion
  • Chromosomal anomalies known at the time of inclusion
  • No realistic hope for survival at the time of inclusion
  • Gastrointestinal malformation known at the time of inclusion
  • Participation in another intervention trial aiming at having an effect on growth, nutrition, feeding intolerance or severe complications such as NEC and sepsis
  • Infants having nutrient fortifier or formula prior to randomisation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03797157


Contacts
Layout table for location contacts
Contact: Thomas R Abrahamsson, MD, PhD +46709566815 thomas.abrahamsson@liu.se
Contact: Magnus Domellöf, MD, PhD magnus.domellof@umu.se

Sponsors and Collaborators
Thomas Abrahamsson
Sahlgrenska University Hospital, Sweden
Region Uppsala
Vasterbottens lans landsting
Prolacta Bioscience
Investigators
Layout table for investigator information
Principal Investigator: Thomas R Abrahamsson, MD, PhD Region Ostergotland

Layout table for additonal information
Responsible Party: Thomas Abrahamsson, Principal Investigator, Md PhD, Ostergotland County Council, Sweden
ClinicalTrials.gov Identifier: NCT03797157     History of Changes
Other Study ID Numbers: RegionOstergotland
First Posted: January 9, 2019    Key Record Dates
Last Update Posted: January 9, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Enterocolitis
Enterocolitis, Necrotizing
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases